Global Regenerative Medicine Market 2024–2033

Reports Description

As per the current market research conducted by the CMI Team, the global Regenerative Medicine Market is expected to record a CAGR of 22.8% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 65.08 billion. By 2032, the valuation is anticipated to reach USD 174. 72 billion.

The global regenerative medicine market refers to a branch of medicine that assists in methodology in repairing, re-growing, or replacing injured or diseased tissues, organs, or cells. The major pharmaceutical players in the regenerative medicine market concentrate on building strategic partnerships, collaborations, and expansions in favorable regions.

Global Regenerative Medicine Market – Significant Growth Factors

The upward surge in the regenerative medicine market in the coming years can be attributed to the increasing prevalence of chronic ailments and growing awareness of regenerative therapies like tissue, stem cell, and gene editing.

• Rise in chronic diseases: The beginning of common chronic diseases is the loss of cells. For instance, Alzheimer’s disease relates to the loss of brain cells. Regenerative medicine thus becomes a way to uproot the cause of the disease by aiding the body’s natural capacity to repair lost cells and tissue and restore normal functioning.

• Growing incidence of genetic disorders: The therapy of gene editing offers hope for patients suffering from incurable diseases, particularly genetic disorders.

• Rapidly increasing trauma cases: The number of people with bone injuries such as arthritis, osteoporosis, and severe limb trauma injuries, besides musculoskeletal disorders, is increasing.

• Growing investment: There is now global recognition and support for research and development in the regenerative medicine field. The North American region leads, followed by the countries that are a part of the Asia-Pacific region.

• Strong product pipeline: The major pharmaceutical companies are carrying out intensive trials at their research centers and expanding their regenerative medicine products. They are looking at collaborations and partnerships to strengthen their presence. In December 2021, Pfizer, Inc. invested USD 68.5 million in a new state-of-the-art facility in Durham to expand its work in gene therapies. This initiative was expected to help strengthen the company’s presence in the U.S.

Overall, these factors will back the worldwide growth of the regenerative medicine market.

Global Regenerative Medicine Market – Mergers and Acquisitions

The key players in the regenerative medicine market emphasize integrating newer companies into their fold, to foster the growth of their research and development centers. Some of the key acquisitions in recent years are:

• Astellas Pharma Acquisition of CellSight: In June 2021, Astellas Pharma acquired CellSight, a regenerative medicine company focused on developing cell therapies. This move will help Astellas Pharma to make significant strides in the segment of cell therapy.

• AstraZeneca Acquisition of Alexicon and Acerta Pharma: The British-Swedish pharma major has acquired 15 new companies that will give it an edge in many segments including rare diseases, vascular disorders, oncology, and cardiology. Astra Zenca acquired Alexion in December 2022, and Acerta Pharma in 2015.

• Integra LifeSciences Acquisition of Surgical Innovation Associates: In December 2022, Integra LifeSciences acquired Surgical Innovation Associates company. The acquisition is deemed a strategic move that will empower Integra Lifesciences to innovate and lead in implant-based breast reconstruction procedures. The company has also invested in multiple sectors like wound care, orthopedics, and neurology.

These acquisitions have allowed pharma companies to expand their product offerings, reach new markets, and strengthen their positions in the global regenerative medicine market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

 Global Regenerative Medicine Market – Significant Threats

The regenerative medicine market faces several significant threats that could restrain its growth and profitability. Some of these threats include:

• Lack of skilled manpower: With the growth in the regenerative medicine market, a commensurate increase in skilled labor force was expected. However, a gap is seen in the rapidly growing bio-manufacturing segment and the availability of skilled personnel.

• High cost: The high cost of the therapies is another factor restricting the market expansion. The emerging tissue engineering industry faces the challenges of monopolistic practices because of scarcity in the availability of medicines. This, in turn, leads to a rise in cost because of less competition amongst the suppliers.

• Regulation: When it comes to matching the pace of development and innovation taking place in gene and cell therapies, the policy and regulation lag. Often the developers, regulators, and those in the manufacturing sector face the challenge of standardizing the processes that allow the transition of smaller batches of therapies for use in clinical trials into larger batches for commercialization purposes.

Overall, the pharma companies and the governing bodies need to address the issues of skilled personnel and expensive therapies which could have an impact on the expansion and growth of the regenerative medicine market.

Report Scope

Category-wise Insights

By Product:

• Serum-free Media: Serum-free media aids in the growth of a definite cell type or functions as a specific application in the absence of serum. Its advantages include consistent performance, increased growth, and productivity.

• Classical Media: The classical media are considered the first generation of cell culture media. They are used to foster the growth of cells and cell lines and are an important part of the research work done in cell culture.

• Stem Cell Culture Media: The stem cell culture media comprises specialized solutions that aid in the proliferation of stem cells. They also support in growth, cryopreservation, and differentiation of cells.

• Specialty Media: The specialty media plays an important role in optimizing cell proliferation and maintenance. These specialized cell types have diverse nutritional requirements. Thus the specialty media products include protein-based, cell, and virus-based applications.

• Chemically Defined Media: The chemically defined medium means a medium in which the chemicals used are known. No plant, yeast, or animal tissue is present in the composition. Some of its features include reproducibility and control of performance in cell culture, as well as productivity and product quality.
• Other Cell Culture Media: In cell culture media, an adequate source of energy and compounds that are necessary to regulate the cell cycle, are found. A specific culture medium comprises a combination of amino acids, glucose, serum, inorganic salts, and vitamins.

By Type:

• Liquid Media:  Liquid media, also called broths, do not have a solidifying agent. Their role is to foster uniform growth of bacterial strains and is used in fermentation and microorganism studies.

• Semi-solid Media: The semi-solid media are used in the study of the motility of bacteria. They have a soft, custard-like consistency. They are employed in distinguishing between typhoid and colon bacilli in stab cultures.

• Solid Media: The solid media are formulated using an inert solidification agent called agar. They are used to grow microorganisms in their full physical form and prepare bacterial pure cultures.

 Global Regenerative Medicine Market – Regional Analysis

The regenerative medicine market can be analyzed based on the geographical distribution of its research centers, availability of funding by both government and private players, and expenditure on healthcare.

• In 2022, the region of North America dominated the regenerative medicine market by capturing a market share of 32%. Among the countries in North America, the U.S. is the largest contributor to the growth, Canada offers a productive location and Mexico has a well-established research and development infrastructure.

• The growth is a result of various factors including the availability of government and private funding for development; accessibility and usage of advanced technology; and high healthcare spending in the region. Besides, there are several ongoing clinical trials by important market players that have contributed to the region’s growth.

• The market in the North American region is in a progressive stage because the clinical trials of the therapies are in their third phase.

• The government bodies have a favorable outlook for reimbursement and regulatory policies that are fulfilling the growth in the need for regenerative products of tissue engineering. As far as the technology of stem cells is concerned, ethical issues have been raised. This has led to strict regulatory policies affecting the expansion of the market.

• After North America, the Asia-Pacific region is expected to see a surge in the growth rate. This can be attributed to increasing healthcare expenditure and growing investment by major manufacturers to launch new products.

• The region of Asia-Pacific has registered a growth of USD 1,549 million in 2020. It is anticipated to expand at a registered CAGR of 26.6% in the period from 2022 to 2030. The region comprises countries like China, Indonesia, Thailand, India, Japan, New Zealand, Myanmar, and Australia.

• In this region, Japan leads the market followed by China. Due to the increase in its elderly population, Australia has higher healthcare costs.

• The Asia-Pacific region influences the market because of its varied culture and demography. The high incidence rate of unintentional trauma injuries has spurred the growth of the regenerative medicine market.

Overall, there is an increasing potential in developed and developing economies for the regenerative medicine market. The key pharma companies have adopted numerous developmental strategies such as product launches, approval, agreements, partnerships, and mergers. Although the market faces ethical challenges due to unfavourable norms, these countries are expected to address the issues positively.

Global Regenerative Medicine Market – Competitive Landscape

The global regenerative medicine market is highly competitive and several key players are leading and innovating in the technology that could make lives easier for patients. Some of the important pharmaceutical companies are:

• AstraZeneca Plc: AstraZeneca has recognized that cell therapies are the need of the hour. It is focused on bringing about advancements in the field to patients suffering from liver and heart diseases. It is located in Cambridge, United Kingdom.

• Hoffmann-La Roche Ltd.: A major company in biotechnology, F. Hoffman-La Roche Ltd offers pharmaceutical drugs for the treatment of central nervous system disorders, infectious diseases, cancer, and other auto-immune diseases. It is based in Basel, Switzerland.

• Integra Lifesciences Corp.: Based in New Jersey, United States, Integra Lifesciences Corp is one of the foremost companies supplying regenerative technologies, neurosurgical solutions, and surgical instrumentation. It also assists in offering products that help patients with brain injuries, hemorrhagic stroke, and brain tumours.

• Astellas Pharma Inc.: The Tokyo, Japan-based pharma major is focused on the ocular segment and committed to manufacturing therapies for those suffering from vascular diseases, autoimmune conditions, and cancer.

• Bayer AG: The healthcare company is working on therapies and treatments for patients suffering from chronic kidney issues, heart-related ailments, and vision conditions. Bayer AG is located in Leverkusen, Germany.

• Pfizer Inc.: The New York, US-based company is focused on helping patients with rare diseases, inflammation, and immunology. Pfizer is also known worldwide for developing vaccines.

• Merck KGaA: The healthcare company actively works on pharma and biopharma technologies in areas like gene editing. It also focuses on neurology and immunology segments of healthcare, besides fertility and oncology. Merck KGaA is located in Darmstadt, Germany.

• Novartis AG: Novartis AG, a Switzerland company, has more than 20 products in the pipeline for its gene therapy. It has developed a manufacturing process that will address the concerns emerging from rare genetic disorders.

Other prominent players in the global regenerative medicine market include AstraZeneca Plc, Astellas Pharma, Cook Biotech, GlaxoSmithKline, NuVasive, Inc., and Abbott. These companies compete based on technology, innovation, products, and pricing to increase their market share.

The Regenerative Medicine Market is segmented as follows:

By Product

• Gene Therapies
• Cell Therapies
• Tissue-Engineering
• Small Molecules & Biologics

By Material

• Synthetic material
  • Biodegradable synthetic polymers
  • Scaffold
  • Artificial Vascular Graft
  • Materials Hydrogel Material
• Biologically derived material
  • Collagen
  • Xenogeneic material
• Genetically Engineered Material
  • Deoxyribonucleic Acid Transfection Vectors
  • Genetically Manipulated Cell
  • Three-Dimensional Polymer Technology
  • Transgenics
  • Fibroblast
  • Neural Stem Cell
  • Gene-Activated Matrices
• Pharmaceutical
  • Biologics
  • Small Molecules

By Application

• Wound Care
• Musculoskeletal
• Ophthalmology
• Oncology
• Cardiovascular
• Dermatology
• Neurology
• Others

By End User

• Hospitals & Clinics
• Commercial Industries
• Government & Academic Research Institutes

By Region

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America